期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Experimental Studies of the Therapeutic Effect of Gypsophila Oldhamiana Gypsogenin on Lewis Lung Cancer in Mice 被引量:1
1
作者 Guihong Tian Ling Zhou Ying Zhong Wan Xu Hong Bai Lu Liu Shuxiang Cui 《Chinese Journal of Clinical Oncology》 CSCD 2008年第3期206-210,共5页
OBJECTIVE To observe the inhibitory effect of Gypsophila oldhamiana gypsogenin (GOG) on Lewis lung cancer growth,and to investigate the mechanism of its anti-tumor effect. METHODS A mouse model bearing Lewis lung canc... OBJECTIVE To observe the inhibitory effect of Gypsophila oldhamiana gypsogenin (GOG) on Lewis lung cancer growth,and to investigate the mechanism of its anti-tumor effect. METHODS A mouse model bearing Lewis lung cancer was used.The 5 experimental groups were divided into a positive control (cis-diaminedichloroplatinum),a negative control,and high,medium and low-GOG dosage groups.The inhibitory action of GOG administration on the lung cancer was observed.After GOG treatment,the lungs were taken out and a lung coefficient computed.The expressions of VEGF,Bcl-2,Bax and P53 in the cancers were determined using immunohistochemical staining. RESULTS The tumor weight of the mice given various doses of GOG was significantly lower compared to the negative-control group (P<0.01),and the lung coefficient of the groups given high and low GOG doses was significantly lower compared to the negative-control group (P<0.01).Immunohistochemical results were shown as follows:i) The VEGF and Bcl-2 expressions in the GOG groups were significantly lower than that of the negative-control group (P<0.05);ii) Bax expression in the groups treated with high and medium GOG doses was significantly higher compared to the negative-control group (P<0.05);iii) The mutant P53 expression in the GOG-treated groups was significantly lower compared to the negative-control group (P<0.05).CONCLUSION GOG can inhibit the growth and metastasis of Lewis lung cancer,and may exert its mechanism of tumor control by inhibition of tumor angiogenesis and induction of apoptosis. 展开更多
关键词 Gypsophila oldhamiana gypsogenin Lewis lungcancer tumor growth tumor metastasis.
下载PDF
Urchin-like Na-doped zinc oxide nanoneedles for low-concentration and exclusive VOC detections
2
作者 Yiwen Zhou Yifan Luo +5 位作者 Zichen Zheng Kewei Liu Xiaoxi He Kaidi Wu Marc Debliquy Chao Zhang 《Journal of Advanced Ceramics》 SCIE EI CAS CSCD 2024年第4期507-517,共11页
In the early-stage diagnosis of lung cancer,the low-concentration(<5 ppm)volatile organic compounds(VOCs)are extensively identified to be the biomarkers for breath analysis.Herein,the urchin-like sodium(Na)-doped z... In the early-stage diagnosis of lung cancer,the low-concentration(<5 ppm)volatile organic compounds(VOCs)are extensively identified to be the biomarkers for breath analysis.Herein,the urchin-like sodium(Na)-doped zinc oxide(ZnO)nanoneedles were synthesized through a hydrothermal strategy with the addition of different contents of citric acid.The Na-doped ZnO gas sensor with a 3:1 molar ratio of Na^(+)and citric acid showed outstanding sensing properties with an optimal selectivity to various VOCs(formaldehyde(HCOH),isopropanol,acetone,and ammonia)based on working temperature regulation.Specifically,significantly enhanced sensitivity(21.3@5 ppm)compared with pristine ZnO(~7-fold),low limit of detection(LOD)(298 ppb),robust humidity resistance,and long-term stability of formaldehyde sensing performances were obtained,which can be attributed to the formation of a higher concentration of oxygen vacancies(20.98%)and the active electron transitions.Furthermore,the improved sensing mechanism was demonstrated by the exquisite band structure and introduction of the additional acceptor level,which resulted in the narrowed bandgap of ZnO. 展开更多
关键词 zinc oxide(ZnO) heterovalent ions doping citric acid gas sensor volatile organic compound(VOC)detection lungcancer
原文传递
Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022
3
作者 Shi-Peng Ke Si-Mei Chen +7 位作者 Yi Jiang Heng-Xin Gong Jia-Li Yu Xu Li Yin-Yi Chen Xiao-Hang Li Qun-Xia Wang Yan-Zhao Liu 《Cancer Innovation》 2023年第4期265-282,共18页
Background Lung cancer(LC)is the leading cause of cancer-related deaths worldwide.Tumor marker(TM)detection can indicate the existence and growth of a tumor and has therefore been used extensively for diagnosing LC.He... Background Lung cancer(LC)is the leading cause of cancer-related deaths worldwide.Tumor marker(TM)detection can indicate the existence and growth of a tumor and has therefore been used extensively for diagnosing LC.Here,we conducted a bibliometric analysis to examine TM-related publications for LC diagnosis to illustrate the current state and future trends of this field,as well as to identify additional promising TMs with high sensitivity.Methods Publications regarding TMs in LC diagnosis were downloaded from the Web of Science Core Collection.CiteSpace was applied to perform a bibliometric analysis of journals,cocitation authors,keywords,and references related to this field.VOSviewer was used to generate concise diagrams about countries,institutions,authors,and keywords.Changes in the TM research frontier were analyzed through citation burst detection.Results A total of 990 studies were analyzed in this work.The collaboration network analysis revealed that the People's Republic of China,Yonsei University,and Molina R were the most productive country,institution,and scholar,respectively.Additionally,Molina R was the author with the most citations.The National Natural Science Foundation of China was the largest funding source.“Carcinoembryonic antigen(CEA)as tumor marker in lung cancer”was the top reference with the most citations,Lung Cancer was the core journal,and“serum tumor marker”experienced a citation burst over the past 5 years.Conclusion This bibliometric analysis of TMs in LC diagnosis presents the current trends and frontiers in this field.We summarized the research status of this field and the methods to improve the diagnostic efficacy of traditional serum TMs,as well as provided new directions and ideas for improving the LC clinical detection rate.Priority should be given to the transformation of computer-assisted diagnostic technology for clinical applications.In addition,circulating tumor cells,exosomes,and microRNAs were the current most cutting-edge TMs. 展开更多
关键词 bibliometric analysis CITESPACE DIAGNOSIS lungcancer TUMORMARKER
下载PDF
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer 被引量:66
4
作者 Kaichao Feng Yelei Guo +4 位作者 Hanren Dai Yao Wang Xiang Li Hejin Jia Weidong Han 《Science China(Life Sciences)》 SCIE CAS CSCD 2016年第5期468-479,共12页
The successes achieved by chimeric antigen receptor-modified T (CAR-T) cells in hematological malignancies raised the pos- sibility of their use in non-small lung cancer (NSCLC). In this phase I clinical study (N... The successes achieved by chimeric antigen receptor-modified T (CAR-T) cells in hematological malignancies raised the pos- sibility of their use in non-small lung cancer (NSCLC). In this phase I clinical study (NCT01869166), patients with epidermal growth factor receptor (EGFR)-positive (〉50% expression), relapsed/refractory NSCLC received escalating doses of EGFR-targeted CAR-T cell infusions. The EGFR-targeted CAR-T cells were generated from peripheral blood after a 10 to 13-day in vitro expansion. Serum cytokines in peripheral blood and copy numbers of CAR-EGFR transgene in peripheral blood and in tissue biopsy were monitored periodically. Clinical responses were evaluated with RECISTI.1 and im- mune-related response criteria, and adverse events were graded with CTCAE 4.0. The EGFR-targeted CAR-T cell infusions were well-tolerated without severe toxicity. Of 11 evaluable patients, two patients obtained partial response and five had stable disease for two to eight months. The median dose of transfused CAR+ T cells was 0.97x 10^7 cells kg J (interquar- tile range (IQR), 0.45 to 1.09x 10^7 cells kg 1). Pathological eradication of EGFR positive tumor cells after EGFR-targeted CAR-T cell treatment can be observed in tumor biopsies, along with the CAR-EGFR gene detected in tumor-infiltrating T cells in all four biopsied patients. The EGFR-targeted CAR-T cell therapy is safe and feasible for EGFR-positive advanced re- lapsed/refractory NSCLC. 展开更多
关键词 chimeric antigen receptor IMMUNOTHERAPY epidermal growth factor receptor RELAPSED/REFRACTORY non-small cell lungcancer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部